Author Archives: gutsandgrowth

Unknown's avatar

About gutsandgrowth

I am a pediatric gastroenterologist at GI Care for Kids (previously called CCDHC) in Atlanta, Georgia. The goal of my blog is to share some of my reading in my field more broadly. In addition, I wanted to provide my voice to a wide range of topics that often have inaccurate or incomplete information. Before starting this blog in 2011, I would tear out articles from journals and/or keep notes in a palm pilot. This blog helps provide an updated source of information that is easy to access and search, along with links to useful multimedia sources. I was born and raised in Chattanooga. After graduating from the University of Virginia, I attended Baylor College of Medicine. I completed residency and fellowship training at the University of Cincinnati at the Children’s Hospital Medical Center. I received funding from the National Institutes of Health for molecular biology research of the gastrointestinal tract. During my fellowship, I had the opportunity to work with some of the most amazing pediatric gastroenterologists and mentors. Some of these individuals included Mitchell Cohen, William Balistreri, James Heubi, Jorge Bezerra, Colin Rudolph, John Bucuvalas, and Michael Farrell. I am grateful for their teaching and their friendship. During my training with their help, I received a nationwide award for the best research by a GI fellow. I have authored numerous publications/presentations including original research, case reports, review articles, and textbook chapters on various pediatric gastrointestinal problems. In addition, I have been recognized by Atlanta Magazine as a "Top Doctor" in my field multiple times. Currently, I am the vice chair of the section of nutrition for the Georgia Chapter of the American Academy of Pediatrics. In addition, I am an adjunct Associate Clinical Professor of Pediatrics at Emory University School of Medicine. Other society memberships have included the North American Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN), American Academy of Pediatrics, the Food Allergy Network, the American Gastroenterology Association, the American Association for the Study of Liver Diseases, and the Crohn’s and Colitis Foundation. As part of a national pediatric GI organization called NASPGHAN (and its affiliated website GIKids), I have helped develop educational materials on a wide-range of gastrointestinal and liver diseases which are used across the country. Also, I have been an invited speaker for national campaigns to improve the evaluation and treatment of gastroesophageal reflux disease, celiac disease, eosinophilic esophagitis, hepatitis C, and inflammatory bowel disease (IBD). Some information on these topics has been posted at my work website, www.gicareforkids.com, which has links to multiple other useful resources. I am fortunate to work at GI Care For Kids. Our group has 17 terrific physicians with a wide range of subspecialization, including liver diseases, feeding disorders, eosinophilic diseases, inflammatory bowel disease, cystic fibrosis, DiGeorge/22q, celiac disease, and motility disorders. Many of our physicians are recognized nationally for their achievements. Our group of physicians have worked closely together for many years. None of the physicians in our group have ever left to join other groups. I have also worked with the same nurse (Bernadette) since I moved to Atlanta in 1997. For many families, more practical matters about our office include the following: – 14 office/satellite locations – physicians who speak Spanish – cutting edge research – on-site nutritionists – on-site psychology support for abdominal pain and feeding disorders – participation in ImproveCareNow to better the outcomes for children with inflammatory bowel disease – office endoscopy suite (lower costs and easier scheduling) – office infusion center (lower costs and easier for families) – easy access to nursing advice (each physician has at least one nurse) I am married and have two sons (both adults). I like to read, walk/hike, bike, swim, and play tennis with my free time. I do not have any financial relationships with pharmaceutical companies or other financial relationships to disclose. I have helped enroll patients in industry-sponsored research studies.

Transient Elastography in Pediatric Liver Disease

Posted on by

AM Banc-Husu, LM Bass. JPGN 2021; 73: 141-144. Transient Elastography in Pediatric Liver Disease

This useful review explains the techniques/technologies/limitations of transient elastography and provides pediatric values which correlate with liver fibrosis. Confounding factors, however, may affect elastography measurements, such as obesity, severe inflammation, nonfasting state, and hepatic congestion.

From Table 2 for Elastography (FibroScan technology) Cut-Off Values and Correlation with Outcomes :

  • Biliary Atresia: >15.5 kPa distinguishes METAVIR F4 fibrosis and >12.7 kPa predicts development of varices
  • Any Chronic Liver disease: >10.6 kPa distinguishes METAVIR F2 fibrosis
  • Non-alcoholic fatty liver disease: >9 kPa distinguishes advanced fibrosis
  • Portal hypertension: >9.7 kPa distinguishes presence of portal hypertension
  • Liver transplant graft: >5.6 kPa distinguishes advanced fibrosis

My take: Elastography is most useful when values are at the very low and very high end. Low values provide a lot of reassurance against significant fibrosis and high values indicate a high likelihood of significant liver fibrosis.

Related blog post:

From Shelburne Farms (https://shelburnefarms.org/) Vermont

Pelvic AnoRectal Care Program (PARC)

Posted on by

I recently had the opportunity to hear a terrific lecture by Kathleen Hoff regarding efforts to achieve continence for children, especially those with anorectal malformations. This blog entry has abbreviated/summarized the presentation. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.

Key points (my notes followed by screenshots of some of the slides):

How to reach PARC team:

Data from PARC: Red color indicates use of enemas, light brown indicates use of laxatives
Products for enemas
Data showing increasing use of antegrade enemas in older children
and those with moderate and complex malformations

Related blog posts:

“Turning Purple with Pain”

Posted on by

A recent clinical problem-solving case (TW Fredrick et al. NEJM 2021; 385; 549-554. Turning Purple with Pain) is a good review on episodic pain and acute intermittent porphyria (AIP).

The case presentation regarded a 32 yo with episodic severe pain for 10 years (associated with constipation) that required morphine. Episodes occurred every month or two and lasted for several days. Some clues in this case included the development of hyponatremia, purple urine, and an episode in which she was “out of it.” This episode was attributed to opioid use and providers were concerned about opioid-seeking behavior and a conversion disorder.

She had extensive evaluations including imaging, panendoscopy, and labs. Atypical labs included serum tryptase, cortisol, and C1 esterase inhibitor level. Ultimately, her constellation of findings led to a urine porphyrin levels which disclosed elevated porphobilinogen (PBG) and delta-aminolevulinic acid. The diagnosis of AIP was confirmed with genetic testing.

Key points:

  • AIP results from mutations in HMBS, the gene encoding hydroxymethylbilane synthase which plays an integral role in heme synthesis
  • AIP is rare, affecting about 5 people per million; age of onset is typically 18-45 years of age
  • In a case series, 18% of patients with AIP reported nearly constant abdominal pain symptoms, 73% had nausea/vomiting, 60% have constipation, and 55% had anxiety/depression.
  • Associated conditions included hypertension ((43%), peripheral neuropathy (43%), chronic kidney disease (29%), psychiatric disorders (22%), palpitations (19%), seizures (9%), cirrhosis (2%), and hepatocellular carcinoma (1%)
  • Flares of AIP may be triggered by alcohol, infections, low caloric intake, and medications (especially seizure medications and hormonal contraceptives)
  • The urine can appear red or brown and darkens on exposure to oxygen, light or heat. Purple urine reflects very high urinary PBG levels

My take: This article provides a useful overview. AIP needs to be considered in adolescents with severe abdominal pain that results in hospitalization (especially if episodic).

Related blog post: Liver Shorts -June 2020 (with AIP article)

Also, data supporting COVID-19 effectiveness in reducing the risk of hospitalization–CDC study shows unvaccinated people are 29 times more likely to be hospitalized with Covid (CNBC)

Sterling Pond. Jeffereson, VT

Long-Haul COVID: ‘Next Health Disaster’

Posted on by

S Phillips, MA Wiliams. NEJM 2021; 385: 577-579. Open Access: Confronting Our Next National Health Disaster — Long-Haul Covid

A few excerpts:

  • Factoring in new infections in unvaccinated people, we can conservatively expect more than 15 million cases of long Covid resulting from this pandemic. And though data are still emerging, the average age of patients with long Covid is about 40, which means that the majority are in their prime working years.
  • Long Covid is not a condition for which there are currently accepted objective diagnostic tests or biomarkers…The health care community, the media, and most people with long Covid have treated this syndrome as an unexpected new phenomenon. But given the long arc and enigmatic history of “new” postinfection syndromes, the emergence of long Covid should not be surprising.
  • Equally unsurprising has been the medical community’s ambivalence about recognizing long Covid as a legitimate disease or syndrome…If the past is any guide, they will be disbelieved, marginalized, and shunned by many members of the medical community…Some of the disregard can be attributed to the fact that long Covid has disproportionately affected women.
  • The ultimate success of the research-and-development and clinical management agendas in ameliorating the impending catastrophe is critically dependent on health care providers’ believing and providing supportive care to their patients. These beleaguered patients deserve to be afforded legitimacy, clinical scrutiny, and empathy.

My take: It is unfortunate that many cases of long-haul Covid that will develop could be prevented with vaccination

Causeway Trail in Burlington VT (adjacent to Lake Champlain)

Pediatric Gastroenterology Opportunities at GI Care For Kids

Posted on by
This image has an empty alt attribute; its file name is image-79.png

Job Openings: Pediatric Gastroenterologists

Description

GI Care For Kids is seeking multiple experienced Pediatric Gastroenterologists to join our group of 15 pediatric gastroenterologists and 5 advanced practice providers.  Our highly-regarded and busy private practice provides state-of-the art, comprehensive care in our offices and at Children’s Healthcare of Atlanta at Scottish Rite, located across the street from our main office. 

Our group includes general pediatric gastroenterologists as well as physicians with a wide range of subspecialization, including inflammatory bowel disease, short bowel syndrome, eosinophilic diseases, motility disorders, feeding disorders, aerodigestive disorders, and celiac disease.  Many of our physicians are recognized nationally for their achievements.  With our clinical colleagues at Children’s Healthcare of Atlanta, we are rated as the #8 pediatric gastroenterology program in the country by U.S. News.  

Important features of our practice include the following:


  • 13 office/satellite locations.  All physicians help cover satellite locations.
  • opportunity for cutting edge clinical research
  • currently >12 pharmaceutical trials for IBD, EoE, IBS, and Clostridium difficile
  • on-site nutritionists
  • on-site psychology support for patients
  • participation in ImproveCareNow
  • fully-accredited office-based pediatric endoscopy center
  • office infusion centers
  • multi-lingual physicians
  • EPIC electronic health record system

We are looking for candidates with prior clinical experience (prefer 2 or more years after fellowship) and excellent communication skills.  Additional expertise in advanced endoscopy or pancreatic specialization would be ideal but not a requirement for consideration.  All candidates should be board-certified in pediatric gastroenterology.

The Atlanta area is a thriving city (except during a snowstorm) with excellent schools and recreational opportunities.  Our office offers competitive salary, benefits, vacation time (20 work days including CME time), and partnership opportunity. Compensation package includes family health insurance, profit sharing, and CME allowance.  Hospital coverage averages 1 week/1 weekend per month. Night call is shared and averages about 2 nights per month.  Our group is committed to fostering a diverse, equitable, inclusive, and family-friendly environment in which all physicians and staff can excel and achieve work/life balance.

Please send letter of interest and curriculum vitae to: Katrin Herzog. Email address:  kherzog@gicareforkids.com

Calprotectin Less Accurate for Isolated Ileal Crohn’s Disease

Posted on by

G D’Arcangelo et al. JPGN 2021; 73: 242-246. Is Fecal Calprotectin a Useful Marker for Small Bowel Crohn Disease?

In this retrospective study with 98 patients, the authors examined the sensitivity and specificity of fecal calprotectin (FC) at a cutoff of 150 mcg/g in comparison to findings of ileocolonoscopy and MRE in those with isolated ileal CD (L1, n=14), colonic CD (L2, n=10) and ilecolonic CD (L3, n=74) . Note: the abstract erroneously states the cutoff as 50 mcg/g.

Key findings:

  • The sensitivity and specificity of FC for L1 CD were 36% and 91%, respectively, compared to 93% and 75% for L2 and 70% and 95% for L3.
  • An FC of 95 mg/kg was identified as the best cut off for identification of active isolated ileal disease, with a sensitivity of 77% and a specificity of 56%

My take: Though this study had only 14 patients with isolated ileal disease, it is likely that a calprotectin level is less reliable as a biomarker in these patients.

Related article: Jukic A, Bakiri L, Wagner EF, et al Calprotectin: from biomarker to biological functionGut Published Online First: 18 June 2021. doi: 10.1136/gutjnl-2021-324855. Thanks to KT Park for this reference. Open Access- Full text: Calprotectin: from biomarker to biological function

Related blog posts:

CDED + PEN: An Alternative Diet to Exclusive Enteral Nutrition?

Posted on by

T Niseteo et al Nutr Clin Pract 2021: 1-7. Modified Crohn’s disease exclusion diet is equally effective as exclusive enteral nutrition: Real-world data Thanks to Kipp Ellsworth for this reference.

This was a retrospective study with 61 children, median age, 14.4 years; overall, 42 (69%) achieved clinical remission based on weighted PCDAI. The study compared a modified Crohn’s disease exclusion diet (CDED) (modified as 80% in this group had 1–2 weeks of EEN initially) to EEN; PEN accounted for ~50% of calories CDED/PEN group received mainly modulen whereas EEN received a number of standard polymeric isocaloric formulas (eg. pediasure, osmolite, ensure plus). Concomitant medical therapy was used in ~80% of patients (most often azathioprine).

Key finding: Clinical remission was similar in both groups: 27 of 41 (65.9%) received EEN and 15 of 20 (75.0%) received CDED + PEN after 6-8 weeks of treatment. In addition, both groups had improvement in CRP and Hemoglobin.

*Several authors grants/payments from formula manufacturers.

My take: This study while favorable towards a combination of CDED/PEN is limited by small numbers, retrospective design, limited followup and absence of data on mucosal healing.

Related blog posts:

K Lambert et al. AP&T 2021; https://doi.org/10.1111/apt.16549. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. Thanks to Ben Gold for this reference.

This meta-analysis included 19 studies of adults with IBD involving dietary intake. Results “show inadequate energy for all subgroups of adults with IBD (mean intake in adults with IBD 1980 ± 130 kcal), as well as fiber (14 ± 4 g), folate (246 ± 33 mg) and calcium (529 ± 114 mg) per day.” Further, “In comparison to the healthy control groups, IBD patients consumed significantly less dietary fiber (SMD −0.59; 95% CI, −0.73 to −0.46).” 

Would You Want a Smart Toilet?

Posted on by

Gastro & Endo News July 2021, Full Text: Disease Surveillance With Every Flush: Introducing the Smart Toilet

Key finding:

  • The Smart Toilet was able to determine the stool consistency and if the stool had blood 85% and 75% accuracy, respectively, in agreement with a gastroenterologist.

An excerpt:

“At the 2021 virtual Digestive Disease Week, Duke University gastroenterologist Deborah Fisher, MD, and engineering professor Sonia Grego, PhD, showed that toilets enabled with artificial intelligence can analyze stool samples for signs of acute or chronic gastrointestinal disease, such as bleeding, infections or even inflammatory bowel disease.”

My take: I definitely do NOT want my toilet to be too smart. It would not be hard to imagine the toilet berating me for what I ate for dinner the night before.

Can Antibiotics Increase the Risk of Antidrug Antibodies to Infliximab?

Posted on by

A lot of research is looking at how alterations in the microbiome affect a plethora of medical outcomes. Recently, there was a study linking sugar consumption in adolescence with an increased risk of adenomas (full text link: Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors; Gastroenterol 2021; 161: 128-142).

Now, a study indicates that taking oral antibiotics can influence the risk of developing antibodies to infliximab.

Full text (open access): Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN (thanks to John Pohl for this reference)

Citation: Gorelik Y, Freilich S, Gerassy-Vainberg S, et al Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRNGut Published Online First: 03 August 2021. doi: 10.1136/gutjnl-2021-325185

This study reviewed data from 1946 patients with 363 who developed anti-drug antibodies (ADA). Then, specific pathogen and germ-free C57BL mice were treated with respective antibiotics and challenged with infliximab. ADA were assessed after 14 days.

Key findings:

  • Cox proportional hazard model demonstrated an increased risk of ADA development in patients who used cephalosporins (HR=1.97, 95% CI 1.58 to 2.44), or penicillins with β-lactamase inhibitors (penicillin-BLI, HR=1.4, 95% CI 1.13 to 1.74), whereas a reduced risk was noted in patients treated with macrolides (HR=0.38, 95% CI 0.16 to 0.86) or fluoroquinolones (HR=0.20, 95% CI 0.12 to 0.35).
  • In mice exposed to infliximab, significantly increased ADA production was observed in cephalosporin as compared with macrolide pretreated mice. Germ-free mice produced no ADA.

My take: The combination of retrospective data and mouse studies suggests that taking some antibiotics (mainly penicillins and cephalosporins) could increase the risk of immunogenicity to infliximab and increase the risk of anti-drug antibodies.